secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0000885725-26-000031
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific Q1 2026 net sales $5.20B (+11.6% reported), adj EPS $0.80 (guidance $0.78-$0.80)
--------------------------------------------------------------------------------

- GAAP EPS $0.90 vs $0.45 YoY; adjusted EPS $0.80 vs $0.75 YoY, at top of guidance.
- Cardiovascular segment net sales $3.50B (+13.5% reported); MedSurg $1.70B (+7.8% reported).
- FY2026 guidance: organic growth 6.5-8.0%; adj EPS $3.34-$3.41. Q2: organic growth 5.0-7.0%; adj EPS $0.82-$0.84.
- WATCHMAN FLX trial (CHAMPION-AF) met all endpoints; FARAPULSE PFA showed superior long-term AF outcomes.
- Acquired Valencia Technologies (eCoin system for urge incontinence); elected Cathy Smith and Christophe Weber to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/0000885725-26-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000031/bsx-20260422.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer